


The V92™ product line is prepared with a novel DMSO-free cryoprotectant, which provides dependable cell identity and the ability to sustain cell viability post-thaw. Final preparation of the cell and bone components yields a product that provides osteoconductive, osteoinductive, and osteogenic properties to enhance the patient's innate healing response.

V92[™] and V92-FC[™] cellular bone matrices are viable allogeneic bone allografts containing viable bone-derived cells. Each product contains the three key elements that are ideal for bone formation:

- An osteoconductive three-dimensional scaffold with cortical and cancellous components.
- A demineralized bone scaffold with osteoinductive potential which provides exposure of signaling molecules and bone morphogenetic proteins.¹
- Bone-derived cells to support osteogenic healing processes.



Features of V92™

- 100 300 µm cortical and cancellous bone microparticulate scaffold blend
- Bone microparticulate scaffold and cell mixture allows for tight packing of defect
- Final handling yields a cohesive, wet sand consistency
- Offered in 1.0, 2.5, 5.0 and 10cc sizes
- Components: Bone Microparticulate Jar, Cell Vial




DISTRIBUTED BY:



PROCESSED BY:
VIVEX Biologics, Inc.
1951 NW 7th Ave, Suite 200,
Miami, FL 33136, U.S.A.
[888]684-7783
vivex.com
customerservice@vivex.com

Features of V92-FC™

- 100 300 µm cortical and cancellous bone microparticulate scaffold blend
- Bone microparticulate scaffold and cell mixture allows for a moldable, paste consistency
- Can easily pass through a large or open bore syringe
- Hydrophobic properties of V92-FC™ make it more resistant to lavage
- Offered in 2.5, 5.0 and 10cc sizes
- Components: Bone Microparticulate Jar, Bone Gel Jar, Cell Vial



Key Features of V92™ and V92-FC™:

- Two (2) unique scaffold blends for optimal handling characteristics: V92™ and V92-FC™
- Proprietary, optimized bone microparticulate size range of 100-300 µm.
- Novel DMSO-free Cryoprotectant, with no rinsing and decanting steps required prior to use.
- Average Cell Viability of the cell component exceeds 80%.²
- Minimum of 150,000 Viable Cells/CC of allograft post-thaw.²
- Convenient Handling and Preparation in the OR, with total preparation time on the back table less than 20 minutes.
- Four (4) hour working window for implantation after thaw without loss of cell viability.
- **Product Shelf Life** is two (2) years from date of processing when stored at -65°C or colder.

Potential Clinical Indications:

Fracture

- Jones
- Talus
- Navicular

Fusion

- TN
- Lesser TMT
- Ankle
- Triple Arthrodesis
- MTP Graft
- Subtalar Fusion Graft



Preoperative x-ray demonstrating non-union of 1st TMT joint



conjunction with V92™

PRESERVE™ Lapidus Allograft used in



Radiographic demonstration of fusion of 1st TMT joint

- Gruskin, E. et.al., Demineralized bone matrix in bone repair: history and use. Advanced Drug Delivery Reviews, 2012. 64: 1063-1077.
- 2. Data on file at VIVEX Biologics, Inc.

Ordering information:

ITEM NUMBER	PRODUCT DESCRIPTION
P01-V92-0100	V92™ Cellular Bone Matrix 1.0 cc
PO1-V92-0250 PO1-V92-0500	V92™ Cellular Bone Matrix 2.5 cc V92™ Cellular Bone Matrix 5.0 cc
PO1-V92-1000	V92™ Cellular Bone Matrix 10.0 cc
PO1-V92-0251	V92-FC™, Bone Matrix 2.5 cc
PO1-V92-0501 PO1-V92-1001	V92-FC™, Bone Matrix 5.0 cc V92-FC™. Bone Matrix 10.0 cc

For the contraindications, warnings, precautions, and potential adverse events associated with this product, please refer to the product-specific instructions for use at http://www.paragon28.com/ifus

™ Trademarks and ® Registered Marks of Paragon 28, Inc. All rights reserved.

Caution: U.S. Federal Law restricts this device to sale by or on order of a physician.

P01-V92-SSPG RevD

To place an order, please contact: orders@paragon28.com 855.786.2828 | www.paragon28.com



PROCESSED BY:
VIVEX Biologics, Inc.
1951 N.W. 7th Ave, Suite 200
Miami, FL 33136, U.S.A.

888.684.7783 305.356.0900 (fax) vivex.com